You are here: Industry Insights > ovarian cancer

News List

FDA accepts Zejula sNDA application as a maintenance treatment for ovarian cancer europeanpharmaceuticalreview
March 04, 2020
The developers of Zejula (niraparib) have announced the FDA will assess the sNDA application under the Real-Time Oncology Review (RTOR) pilot programme.
Lynparza regulatory submission granted Priority Review in the US for 1st-line maintenance treatment with bevacizumab in advanced ovarian cancer worldpharmanews
January 16, 2020
AstraZeneca and MSD Inc., Kenilworth, N.J., US (MSD: known as Merck & Co., Inc. inside the US and Canada) announced that a supplemental New Drug Application for Lynparza (olaparib) in combination with bevacizumab has been accepted and granted ...
Addition of Maintenance Olaparib Slows Advanced Ovarian Cancer drugs
December 19, 2019
Compared with placebo, the addition of olaparib to maintenance therapy with bevacizumab is associated with a significant progression-free survival benefit for patients with ...
AstraZeneca receives Chinese marketing nod for Lynparza biospectrumasia
December 12, 2019
AstraZeneca and MSD have announced that the companies have received marketing authorisation from China’s National Medical Products Administration (NMPA) for Lynparza (olaparib).
AstraZeneca-Merck’s Lynparza approved in China for ovarian cancer pharmaceutical-technology
December 09, 2019
AstraZeneca and Merck (MSD) have received the National Medical Products Administration (NMPA) approval in China for Lynparza (olaparib) to treat ...
AstraZeneca and Merck’s Lynparza continues to perform well in ovarian cancer pharmaceutical-technology
August 16, 2019
AstraZeneca and Merck have announced that Lynparza (olaparib), the primary product in their ongoing oncology collaboration, has performed better than the standard of care as a first line maintenance treatment for patients with ovarian cancer, regardless o
AstraZeneca’s Lynparza gets EU nod as first-line ovarian cancer maintenance treatment expresspharma
June 21, 2019
British drugmaker AstraZeneca announced that its cancer medicine Lynparza was approved as a first-line maintenance treatment for a type of advanced ovarian cancer by the European Commission, following a panel’s consent in April.
Lynparza bags EU approval for RCA-mutated advanced ovarian cancer pharmatimes
June 19, 2019
The data were presented on 21 October 2018, at the Presidential Symposium of the ESMO (European Society for Medical Oncology) 2018 Congress in Munich, Germany and published simultaneously online in The New England Journal of Medicine.
SOTIO’s DCVAC/OvCa Significantly Improves Survival in Patients with Recurrent Ovarian Cancer pharmafocusasia
March 20, 2019
SOTIO, a biotechnology company owned by the PPF Group, presented results from SOV02, its Phase II clinical trial evaluating DCVAC/OvCa, an active cellular immunotherapy product, in patients with recurrent ovarian cancer at 2019 SGO’s 50th Annual Meeting o
Lymphadenectomy Does Not Up Survival in Advanced Ovarian Cancer February 28, 2019
For patients with advanced ovarian cancer who have undergone intra-abdominal macroscopically complete resection and have clinically negative lymph nodes....

Previous page 1 2 3 4 5 6 7 8 Next page